Journal of Bacteriology, November 1999, p. 6922-6928, Vol. 181, No. 22
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Area of Microbiology, Faculty of Biology, University of León, 24071 León, Spain
Received 28 May 1999/Accepted 26 August 1999
The
-lactamase inhibitor clavulanic acid is formed by
condensation of a pyruvate-derived C3 unit with a molecule of arginine. A gene (pyc, for pyruvate converting) located upstream of
the bls gene in the clavulanic acid gene cluster of
Streptomyces clavuligerus encodes a 582-amino-acid protein
with domains recognizing pyruvate and thiamine pyrophosphate that shows
29.9% identity to acetohydroxyacid synthases. Amplification of the
pyc gene resulted in an earlier onset and higher production
of clavulanic acid. Replacement of the pyc gene with the
aph gene did not cause isoleucine-valine auxotrophy in the
mutant. The pyc replacement mutant did not produce clavulanic acid in starch-asparagine (SA) or in Trypticase soy broth
(TSB) complex medium, suggesting that the pyc gene product is involved in the conversion of pyruvate into the C3 unit of clavulanic acid. However, the
-lactamase inhibitor was still formed
at the same level as in the wild-type strain in defined medium
containing D-glycerol, glutamic acid, and proline (GSPG medium) as confirmed by high-pressure liquid chromatography and paper
chromatography. The production of clavulanic acid by the replacement
mutant was dependent on addition of glycerol to the medium, and
glycerol-free GSPG medium did not support clavulanic acid biosynthesis,
suggesting that an alternative gene product catalyzes the incorporation
of glycerol into clavulanic acid in the absence of the Pyc protein. The
pyc replacement mutant overproduces cephamycin.
This article has been cited by other articles:
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |